Difference between revisions of "LINC01138"

From LncRNAWiki
Jump to: navigation, search
 
(3 intermediate revisions by the same user not shown)
Line 14: Line 14:
 
===LncBook transcript ID===
 
===LncBook transcript ID===
 
HSALNT0014603
 
HSALNT0014603
 +
 +
===Characteristics===
 +
-
 +
===Function===
 +
*The high level of LINC01138 is correlated with a short biochemical recurrence-free survival times.<ref name="ref1" />
 +
LINC01138 promotes the proliferation and inhibited apoptosis of PCa.<ref name="ref1" />
 +
LINC01138 functions as an oncogenes in prostate cancer.<ref name="ref1" />
 +
 +
*LINC01138 is associated with the malignant features and poor outcomes of HCC patients. LINC01138 acts as an oncogenic driver that promotes cell proliferation, tumorigenicity, tumour invasion and metastasis by physically interacting with arginine methyltransferase 5 (PRMT5) and enhancing its protein stability by blocking ubiquitin/proteasome-dependent degradation in hepatocellular carcinoma (HCC)<ref name="ref2" />.
 +
 +
===Regulation===
 +
The LINC01138 transcript is stabilized by insulin-like growth factor-2 mRNA-binding proteins 1/3 (IGF2BP1/IGF2BP3)<ref name="ref2" />.
 
===Disease===
 
===Disease===
 
Prostate cancer
 
Prostate cancer
Line 23: Line 35:
  
 
The LINC01138 locus is frequently amplified in hepatocellular carcinoma (HCC)<ref name="ref2" />.
 
The LINC01138 locus is frequently amplified in hepatocellular carcinoma (HCC)<ref name="ref2" />.
===Function===
+
===Sequence===
The high level of LINC01138 is correlated with a short biochemical recurrence-free survival times.<ref name="ref1" />
+
NR_027468.3 Homo sapiens long intergenic non-protein coding RNA 1138 (LINC01138), transcript variant 1, long non-coding RNA
LINC01138 promotes the proliferation and inhibited apoptosis of PCa.<ref name="ref1" />
+
<dnaseq>AGCTGGGCGGTCACATCTGGAAATGGAAAGCCGACCTCCCCCTCCTCCTCCACCTCCTCCTCCTCCTCCT
LINC01138 functions as an oncogenes in prostate cancer.<ref name="ref1" />
+
CCTTCTCCTCCTCTCACCCAGGATCACTTCCGAAACCAGTTGGCCTTCAGCCCCTGCCTCGGCCAGAGGT
 
+
TTCATTTTTAACTGAATATTTACGAAAGCTGAAAGCGTGCGAGGGGGGTGGGGTGGAAATAGCGGCTGCT
LINC01138 is associated with the malignant features and poor outcomes of HCC patients. LINC01138 acts as an oncogenic driver that promotes cell proliferation, tumorigenicity, tumour invasion and metastasis by physically interacting with arginine methyltransferase 5 (PRMT5) and enhancing its protein stability by blocking ubiquitin/proteasome-dependent degradation in HCC<ref name="ref2" />.
+
TCTTTTCCAAGGATTTATTTAATGGGGATGTGTTCAAGGCAAGACCGAATTCAGAAGGATATCGACGTCG
 +
TGATCCAGAAGTCCAGAGCTGAGGACTGCCTGTTTGCAGTTCTGTTTCATCAAATGGAAATGGGACATGG
 +
ACAGTTTCTCCTATCCCATGCAGACCATGCTCCTGAATTAAAACTGCAGAATGTGTTAAAGCATCATTCA
 +
ACATCGTGAGCACATTTGAGATACTGTACAGGACAACCTGCTTTTCATATTCTCTGTGAATTTCAAAGAC
 +
GACTGGGATTTTCTTCCTCCTCTACCACCCTGAACAGCAAGACCAATACATCCTGTATTTCCTCCTCTTC
 +
AGCCTACTTGTGAAGACAAGGATGAAGACCTCCATGATGAGCCATCTCCACTTAATGACTGTCTCACATT
 +
GGCCGGCAACTTGTTCCAGATGAAATCTTGCTCTGTCACCCAGGCTGGAGTGCAATGGCTCGATCTCGGC
 +
TCACTGCAACCTCCACCTTCTGGGTTCAAGCAATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACA
 +
GATGGAGTCTCACTGTGTCCCCAGGCTGGAGTGCAGTGGCGCGATCTCAACTCACTGCAAGCTCTGCCTC
 +
CCGGGTTCACGCCATTCTCCTGCCTCAGGCTCCCGAGTAGCTGGGACTACAGGCGCCCGCCACCACTCCC
 +
GGCTAATTTTTTTTGTATTTTCAGTAGAGACGGGATATCACCATGTTAGCCAGGATGGTCTCGATCTCCT
 +
GACCTCGTGATCCGCCCTCCTCAGTCTCCCAAAGTATTAGGATTACAGGCGTGAGCCACCGCCCCCGGCC
 +
CTCAAAGATTGTTATGAGTCCTCACAGATGTCAGAGGACGATGCTGTGACCTATATTTGCAAACGCCCGG
 +
AAGACTTAAAGCTATTGTTTTGCAAATGCACAGATAACAATAATAACATGATGCTGTGGATGAGCATGAA
 +
AGTTTTTCTCTTACTCCTAATTATAATGTTTTCCCTCTTACTGCTTTGCCCTGCTGATGGAATTCAGTAA
 +
AGGAATCTCTACCAGCAGACACTTGGTTTTTACCCTTCCTAGGACCTTTAATAGATATCTTTTTATTACT
 +
AATCTTTGCTCTTTGCTTGTTTAACCTCCTTGTAAAGTTTGTGTCTTCCAGATTACAATAATTCCATGTA
 +
AAGATGATGCTGGCACAAGGCTTTCAACCCATCCCCTCTTCTGACCCAGAAGATAAAGACATCCTACCTT
 +
TGAGCCTTTTAGAACAGGTATCCAGGGATTTTACCTCTCCAGTGCTAGGCAGGGTCTATGCCCATAACAT
 +
CAGCAGGAAGCAGTTACAGAAGATGAACCTCCGCCCTTCTGCAAGCCCCTTAAGATTAAGGAGGAGTATA
 +
TAATCTCTGATGGGGAAATGAGGTAGGAGACCAGAAGGACTTATTTTCCATTCCCAACCCCATTGAACAG
 +
AGCAGGATCTGGTCAAAACAGGGTGCAGTGGAGAAGCCTGCTGAAACCAGCAGATGATGATGAAAGTGAC
 +
CTCTAGTTGCCCTCACTGCTTATGAGCATAAAGACACTACCACTGGGACCATGGCCAGTTTACAAATGTC
 +
ATGGCAACACACCTTGGCAATGGCCTGGAAGTTACTTTATATGGTTCTGGAAACTCCCTGCCCCTTTCCC
 +
AGAAAGTTCTGAATAACCTACCTCTTAATTGGCATGCAATTAAAAGTGGCTCTAAATACAACTAGCTAGT
 +
AGCCCACAGGCACAAACTCTGGGCACACTGCCTATAGGTTAGCCCTGCTCTGCAAGAAGTAGCACCAGTT
 +
CAATAAAAGTTGCTTTCTCTCAAAAAAAAAAAAAAAAAAAAAAAA</dnaseq>
  
 
==Labs working on this lncRNA==
 
==Labs working on this lncRNA==

Latest revision as of 08:32, 13 August 2019

Annotated Information

Approved Symbol

LINC01138 is associated with clinical outcomes in patients with HCC[1].
Integrated model depicting lncRNA LINC01138 as an oncogene in liver cancer[1].

LINC01138 (long intergenic non-protein coding RNA 1138)

Previous Symbols

LINC00875

Synonyms

FLJ39739

Chromosome

1q21.2

RefSeq(supplied by NCBI)

NR_027468

LncBook transcript ID

HSALNT0014603

Characteristics

-

Function

  • The high level of LINC01138 is correlated with a short biochemical recurrence-free survival times.[2]

LINC01138 promotes the proliferation and inhibited apoptosis of PCa.[2] LINC01138 functions as an oncogenes in prostate cancer.[2]

  • LINC01138 is associated with the malignant features and poor outcomes of HCC patients. LINC01138 acts as an oncogenic driver that promotes cell proliferation, tumorigenicity, tumour invasion and metastasis by physically interacting with arginine methyltransferase 5 (PRMT5) and enhancing its protein stability by blocking ubiquitin/proteasome-dependent degradation in hepatocellular carcinoma (HCC)[1].

Regulation

The LINC01138 transcript is stabilized by insulin-like growth factor-2 mRNA-binding proteins 1/3 (IGF2BP1/IGF2BP3)[1].

Disease

Prostate cancer

Hepatocellular carcinoma (HCC)[1]

Expression

The expression level of LINC01138 is markedly increased in invasive extraprostatic tumors (pT3a, pT3b and T4 stages) as compared with intraprostatic localized tumors (pT2a , pT2b and pT2c stages).[2]

The LINC01138 locus is frequently amplified in hepatocellular carcinoma (HCC)[1].

Sequence

NR_027468.3 Homo sapiens long intergenic non-protein coding RNA 1138 (LINC01138), transcript variant 1, long non-coding RNA

000001 AGCTGGGCGG TCACATCTGG AAATGGAAAG CCGACCTCCC CCTCCTCCTC CACCTCCTCC TCCTCCTCCT CCTTCTCCTC 000080
000081 CTCTCACCCA GGATCACTTC CGAAACCAGT TGGCCTTCAG CCCCTGCCTC GGCCAGAGGT TTCATTTTTA ACTGAATATT 000160
000161 TACGAAAGCT GAAAGCGTGC GAGGGGGGTG GGGTGGAAAT AGCGGCTGCT TCTTTTCCAA GGATTTATTT AATGGGGATG 000240
000241 TGTTCAAGGC AAGACCGAAT TCAGAAGGAT ATCGACGTCG TGATCCAGAA GTCCAGAGCT GAGGACTGCC TGTTTGCAGT 000320
000321 TCTGTTTCAT CAAATGGAAA TGGGACATGG ACAGTTTCTC CTATCCCATG CAGACCATGC TCCTGAATTA AAACTGCAGA 000400
000401 ATGTGTTAAA GCATCATTCA ACATCGTGAG CACATTTGAG ATACTGTACA GGACAACCTG CTTTTCATAT TCTCTGTGAA 000480
000481 TTTCAAAGAC GACTGGGATT TTCTTCCTCC TCTACCACCC TGAACAGCAA GACCAATACA TCCTGTATTT CCTCCTCTTC 000560
000561 AGCCTACTTG TGAAGACAAG GATGAAGACC TCCATGATGA GCCATCTCCA CTTAATGACT GTCTCACATT GGCCGGCAAC 000640
000641 TTGTTCCAGA TGAAATCTTG CTCTGTCACC CAGGCTGGAG TGCAATGGCT CGATCTCGGC TCACTGCAAC CTCCACCTTC 000720
000721 TGGGTTCAAG CAATTCTCCT GCCTCAGCCT CCTGAGTAGC TGGGATTACA GATGGAGTCT CACTGTGTCC CCAGGCTGGA 000800
000801 GTGCAGTGGC GCGATCTCAA CTCACTGCAA GCTCTGCCTC CCGGGTTCAC GCCATTCTCC TGCCTCAGGC TCCCGAGTAG 000880
000881 CTGGGACTAC AGGCGCCCGC CACCACTCCC GGCTAATTTT TTTTGTATTT TCAGTAGAGA CGGGATATCA CCATGTTAGC 000960
000961 CAGGATGGTC TCGATCTCCT GACCTCGTGA TCCGCCCTCC TCAGTCTCCC AAAGTATTAG GATTACAGGC GTGAGCCACC 001040
001041 GCCCCCGGCC CTCAAAGATT GTTATGAGTC CTCACAGATG TCAGAGGACG ATGCTGTGAC CTATATTTGC AAACGCCCGG 001120
001121 AAGACTTAAA GCTATTGTTT TGCAAATGCA CAGATAACAA TAATAACATG ATGCTGTGGA TGAGCATGAA AGTTTTTCTC 001200
001201 TTACTCCTAA TTATAATGTT TTCCCTCTTA CTGCTTTGCC CTGCTGATGG AATTCAGTAA AGGAATCTCT ACCAGCAGAC 001280
001281 ACTTGGTTTT TACCCTTCCT AGGACCTTTA ATAGATATCT TTTTATTACT AATCTTTGCT CTTTGCTTGT TTAACCTCCT 001360
001361 TGTAAAGTTT GTGTCTTCCA GATTACAATA ATTCCATGTA AAGATGATGC TGGCACAAGG CTTTCAACCC ATCCCCTCTT 001440
001441 CTGACCCAGA AGATAAAGAC ATCCTACCTT TGAGCCTTTT AGAACAGGTA TCCAGGGATT TTACCTCTCC AGTGCTAGGC 001520
001521 AGGGTCTATG CCCATAACAT CAGCAGGAAG CAGTTACAGA AGATGAACCT CCGCCCTTCT GCAAGCCCCT TAAGATTAAG 001600
001601 GAGGAGTATA TAATCTCTGA TGGGGAAATG AGGTAGGAGA CCAGAAGGAC TTATTTTCCA TTCCCAACCC CATTGAACAG 001680
001681 AGCAGGATCT GGTCAAAACA GGGTGCAGTG GAGAAGCCTG CTGAAACCAG CAGATGATGA TGAAAGTGAC CTCTAGTTGC 001760
001761 CCTCACTGCT TATGAGCATA AAGACACTAC CACTGGGACC ATGGCCAGTT TACAAATGTC ATGGCAACAC ACCTTGGCAA 001840
001841 TGGCCTGGAA GTTACTTTAT ATGGTTCTGG AAACTCCCTG CCCCTTTCCC AGAAAGTTCT GAATAACCTA CCTCTTAATT 001920
001921 GGCATGCAAT TAAAAGTGGC TCTAAATACA ACTAGCTAGT AGCCCACAGG CACAAACTCT GGGCACACTG CCTATAGGTT 002000
002001 AGCCCTGCTC TGCAAGAAGT AGCACCAGTT CAATAAAAGT TGCTTTCTCT CAAAAAAAAA AAAAAAAAAA AAAAA

Labs working on this lncRNA

  • State Key Laboratory of Genetic Engineering, Shanghai Engineering Research Center Of Industrial Microorganisms, School of Life Science, Fudan University, Shanghai 200433, PR China.
  • Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 Li Z, Zhang J, Liu X, et al. The LINC01138 drives malignancies via activating arginine methyltransferase 5 in hepatocellular carcinoma. Nature communications, 2018, 9(1): 1572.
  2. 2.0 2.1 2.2 2.3 Wan, X., et al., Identification of androgen-responsive lncRNAs as diagnostic and prognostic markers for prostate cancer. Oncotarget, 2016. 7(37): p. 60503-60518.